Literature DB >> 2348382

Evaluation of population (NONMEM) pharmacokinetic parameter estimates.

S Vozeh1, P O Maitre, D R Stanski.   

Abstract

The application of population pharmacokinetic analysis has received increasing attention in the last few years. The main goal of this report is to make investigators aware of the necessity of independent evaluation of the results obtained from a population analysis based on observational studies. We also describe with the help of a specific example (a new synthetic opiate Alfentanil) how such evaluation can be performed for parameter estimates obtained with the software system NONMEM. The method differs depending on the type of serum concentration data that are used for the evaluation. A general method is described, based on the regression model used in NONMEM, that can test for bias in the estimates of fixed and random effects independent of the number of observations per patient and dosing. Since the procedure for testing for statistically significant bias in the prediction of the average concentration and its variability can be relatively complex, we propose that generally available program packages performing estimation of the pharmacokinetic parameters from observational data should contain the necessary software to evaluate the reliability of the parameter estimates on a second data set.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2348382     DOI: 10.1007/bf01063558

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  14 in total

1.  Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery.

Authors:  M E Ausems; C C Hug; D R Stanski; A G Burm
Journal:  Anesthesiology       Date:  1986-10       Impact factor: 7.892

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients.

Authors:  P O Maitre; S Vozeh; J Heykants; D A Thomson; D R Stanski
Journal:  Anesthesiology       Date:  1987-01       Impact factor: 7.892

4.  Intravenous phenytoin: a loading scheme for desired concentrations.

Authors:  K U Blaser; S Vozeh; H Landolt; G Kaufmann; J Romppainen; O Gratzl
Journal:  Ann Intern Med       Date:  1989-06-15       Impact factor: 25.391

5.  An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction.

Authors:  T H Grasela; E J Antal; L Ereshefsky; B G Wells; R L Evans; R B Smith
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

6.  Premarketing observational studies of population pharmacokinetics of new drugs.

Authors:  L B Sheiner; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

7.  Evaluating the accuracy of using population pharmacokinetic data to predict plasma concentrations of alfentanil.

Authors:  P O Maitre; M E Ausems; S Vozeh; D R Stanski
Journal:  Anesthesiology       Date:  1988-01       Impact factor: 7.892

8.  Population pharmacokinetic data and parameter estimation based on their first two statistical moments.

Authors:  S L Beal
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

9.  Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol.

Authors:  W J Jusko; M J Gardner; A Mangione; J J Schentag; J R Koup; J W Vance
Journal:  J Pharm Sci       Date:  1979-11       Impact factor: 3.534

10.  Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus. A population pharmacokinetic study.

Authors:  S Vozeh; T Uematsu; L Aarons; P Maitre; H Landolt; O Gratzl
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

View more
  15 in total

1.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Journal:  AAPS PharmSci       Date:  2002

2.  Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.

Authors:  Dolores Aumente; Dolores Santos Buelga; John C Lukas; Pedro Gomez; Antonio Torres; Maria José García
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Measuring the predictive performance of computer-controlled infusion pumps.

Authors:  J R Varvel; D L Donoho; S L Shafer
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

4.  Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.

Authors:  Kazutaka Yoshihara; Yuying Gao; Hiroshi Shiga; D Russell Wada; Masafumi Hisaoka
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 5.  Population pharmacokinetics. A regulatory perspective.

Authors:  H Sun; E O Fadiran; C D Jones; L Lesko; S M Huang; K Higgins; C Hu; S Machado; S Maldonado; R Williams; M Hossain; E I Ette
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

6.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

7.  Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method.

Authors:  F Mesnil; F Mentré; C Dubruc; J P Thénot; A Mallet
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

8.  A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

Authors:  R Bruno; N Vivier; J C Vergniol; S L De Phillips; G Montay; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

9.  Population pharmacokinetics of ondansetron: a covariate analysis.

Authors:  D P de Alwis; L Aarons; J L Palmer
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

10.  Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.

Authors:  Emmanuelle Comets; Kazumasa Ikeda; Paulo Hoff; Pierre Fumoleau; Jantien Wanders; Yusuke Tanigawara
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.